NEW YORK, NY / ACCESSWIRE / April 5, 2017 / Teva Pharmaceutical Industries and Neurocrine Biosciences will be racing for the FDA approval for their treatments of tardive dyskinesia, revealed an analyst on Tuesday. The disorder is traditionally difficult to treat.

RDI Initiates Coverage on:

Teva Pharmaceutical https://ub.rdinvesting.com/news/?ticker=TEVA

Neurocrine Biosciences https://ub.rdinvesting.com/news/?ticker=NBIX

The drug offered by Teva for the treatment, known as Austedo, gained an approval from FDA on Monday for treating chorea, a common condition related to Huntington's disease, in which the brain's nerve cells begin to break down. Austedo was previously granted orphan drug designation by the FDA. Teva has received a mix of "hold" and "buy" ratings from different investment research firms. An analyst of Credit Sussie expects a 60% chance of Teva gaining FDA approval for its drug. Teva Pharmaceutical Industries shares declined 0.59 percent to close at $32.00 a share on Tuesday. The stock traded between $31.95 and $32.80 on volume of 6.62 million shares traded.

Access RDI's Teva Pharmaceutical Research Report at: https://ub.rdinvesting.com/news/?ticker=TEVA

Teva is set to receive competition from Neurocrine's Ingrezza, which can also be used to treat tardive dyskinesia. The drugs of both the companies have also been pitched for treating Tourette's syndrome, with trials expected later this year to determine their efficiency. For Ingrezza, the FDA will begin the process for approval on April 11th. Neurocrine Biosciences shares declined 0.05 percent to close at $43.22 a share on Tuesday. The stock traded between $43.00 and $44.65 on volume of 1.21 million shares traded.

Access RDI's Neurocrine Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=NBIX

Our Actionable Research on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Neurocrine Biosciences, Inc. (NASDAQ: NBIX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com